PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

Human Pathology

Volumn 47, Issue 1, 2016, Pages 52-63

  Cimino Mathews, Ashley ^a,b   Thompson, Elizabeth ^a   Taube, Janis M ^a   Ye, Xiaobu ^a   Lu, Yao ^a   Meeker, Alan ^a   Xu, Haiying ^a   Sharma, Rajni ^a   Lecksell, Kristen ^a   Cornish, Toby C ^a   Cuka, Nathan ^a   Argani, Pedram ^a   Emens, Leisha A ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Metastatic breast cancer; PD L1; Primary breast cancer; Tumor infiltrating lymphocytes; Tumor microenvironment

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VERY ELDERLY; BREAST NEOPLASMS; CANCER GRADING; CARCINOMA; CHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOCYTE COUNT; METASTASIS; MIDDLE AGED; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TISSUE MICROARRAY; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; T-LYMPHOCYTE SUBSETS; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84951856362     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.09.003     Document Type: Article

References (35)

1. S. Adams, R.J. Gray, S. Demaria, and et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 J Clin Oncol 32 2014 2959 2967
2. S. Loi, S. Michiels, R. Salgado, and et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Ann Oncol 25 2014 1544 1550
3. S.M. Mahmoud, E.C. Paish, D.G. Powe, and et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer J Clin Oncol 29 2011 1949 1955
4. S.M. Mahmoud, A.H. Lee, E.C. Paish, R.D. Macmillan, I.O. Ellis, and A.R. Green The prognostic significance of B lymphocytes in invasive carcinoma of the breast Breast Cancer Res Treat 132 2012 545 553
5. S.M. Mahmoud, E.C. Paish, D.G. Powe, and et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer Breast Cancer Res Treat 127 2011 99 108
6. C. Denkert, S. Loibl, A. Noske, and et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer J Clin Oncol 28 2010 105 113
7. G.J. Bates, S.B. Fox, C. Han, and et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse J Clin Oncol 24 2006 5373 5380
8. C.M. Perou, T. Sorlie, M.B. Eisen, and et al. Molecular portraits of human breast tumours Nature 406 2000 747 752
9. T.O. Nielsen, F.D. Hsu, K. Jensen, and et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 2004 5367 5374
10. A. Rody, T. Karn, C. Liedtke, and et al. A clinically relevant gene signature in triple negative and basal-like breast cancer Breast Cancer Res 13 2011 R97
11. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr Opin Immunol 24 2012 207 212
12. A. Cimino-Mathews, J.B. Foote, and L.A. Emens Immune targeting in breast cancer Oncology (Williston Park) 29 2015 211314
13. Y. Agata, A. Kawasaki, H. Nishimura, and et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes Int Immunol 8 1996 765 772
14. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 1999 1365 1369
15. P.C. Tumeh, C.L. Harview, J.H. Yearley, and et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 2014 568 571
16. R.S. Herbst, J.C. Soria, M. Kowanetz, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
17. J.M. Taube, R.A. Anders, G.D. Young, and et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra37
18. S. Muenst, S.D. Soysal, F. Gao, E.C. Obermann, D. Oertli, and W.E. Gillanders The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer Breast Cancer Res Treat 139 2013 667 676
19. S. Muenst, A.R. Schaerli, F. Gao, and et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer Breast Cancer Res Treat 146 2014 15 24
20. E.A. Mittendorf, A.V. Philips, F. Meric-Bernstam, and et al. PD-L1 expression in triple-negative breast cancer Cancer Immunol Res 2 2014 361 370
21. A. Cimino-Mathews, J.L. Hicks, P.B. Illei, and et al. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy Hum Pathol 43 2012 1003 1011
22. A. Cimino-Mathews, X.B. Ye, A. Meeker, P. Argani, and L.A. Emens Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study Hum Pathol 44 2013 2055 2063
23. J.M. Taube, A. Klein, J.R. Brahmer, and et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 20 2014 5064 5074
24. N. Cuka, H.A. Hempel, K.S. Sfanos, A.M. De Marzo, and T.C. Cornish PIP: an open source framework for multithreaded image analysis of whole slide images Mod Pathol 27 2014 398A
25. H. Ghebeh, E. Barhoush, A. Tulbah, N. Elkum, T. Al-Tweigeri, and S. Dermime FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy BMC Cancer 8 2008 57
26. H. Ghebeh, S. Mohammed, A. Al-Omair, and et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors Neoplasia 8 2006 190 198
27. Z. Gatalica, C. Snyder, T. Maney, and et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type Cancer Epidemiol Biomarkers Prev 23 2014 2965 2970
28. T.F. Gajewski, H. Schreiber, and Y.X. Fu Innate and adaptive immune cells in the tumor microenvironment Nat Immunol 14 2013 1014 1022
29. K.A. Schalper, V. Velcheti, D. Carvajal, and et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas Clin Cancer Res 20 2014 2773 2782
30. R. Salgado, C. Denkert, S. Demaria, and et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 Ann Oncol 26 2015 259 271
31. E.R. Lutz, A.A. Wu, E. Bigelow, and et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation Cancer Immunol Res 2 2014 616 631
32. L. Martinet, I. Garrido, T. Filleron, and et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer Cancer Res 71 2011 5678 5687
33. F. Aloisi, and R. Pujol-Borrell Lymphoid neogenesis in chronic inflammatory diseases Nat Rev Immunol 6 2006 205 217
34. S. Ladoire, L. Arnould, G. Mignot, and et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival Br J Cancer 105 2011 366 371
35. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454